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One third of all breast cancers are diagnosed in women aged 70 or over. Older women are a heterogeneous population who are
under-represented in clinical trials, and as a result uncertainty can exist as to what represents optimal treatment. This minireview,
from an international authorship, summarises the existing evidence surrounding the management of early breast cancer in women
aged 70 and over. The use of primary surgery and endocrine therapy, and adjuvant chemotherapy, radiotherapy, endocrine therapy
and trastuzumab are discussed. Reference is made to ongoing clinical trials in this area and areas of controversy are highlighted.
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In the United Kingdom one third of all breast cancers are
diagnosed in women aged 70 or over, and with the ageing of the
population the number of women in this age group will increase
significantly over the next decade (Cancer Research UK, 2010). It is
well documented that older women with breast cancer are less
likely to be offered or receive standard treatment and that such
undertreatment may impact on disease-specific mortality
(Bouchardy et al, 2007; Lavelle et al, 2007). Older women are also
a very heterogeneous group and are under-represented in clinical
trials (Lewis et al, 2003). These factors lead to uncertainty as to
what represents optimal therapy for these patients. This review
summarises the current evidence base for the treatment of breast
cancer in women aged 70 or over, highlighting where contro-
versies exist.
SURGERY
Surgery is the mainstay of treatment in early breast cancer, but in
older patients clinicians may have concerns about higher rates of
anaesthetic and/or surgical complications. However, the vast
majority of older patients are able to tolerate surgery and
anaesthesia with very low morbidity and almost non-existent
mortality (Wyld and Reed, 2007). When older women do undergo
surgery, they are more likely to undergo mastectomy than younger
women (Mustacchi et al, 2007) and are less likely to be offered or
undergo breast reconstruction (NHS Information Centre, 2010).
These observations may reflect patient choice or concerns over
prolonged anaesthesia. However, it should be recognised that
although cosmesis may be less important to some older women,
most would still choose breast conservation surgery over
mastectomy despite the need for radiotherapy (Sandison et al,
1996).
Axillary staging by axillary lymph node dissection has long been
a standard of care in the surgical management of breast cancer. In
many centres this procedure has been superceded by sentinel node
biopsy, with surgical clearance only performed in those with
positive nodes (although recent data have questioned the need for
completion axillary dissection). Although older patients do not
appear to be at increased risk of complications following axillary
clearance, retrospective analyses and one randomised trial have
questioned its value in older women with breast cancer (IBCSG,
1996). In a randomised trial, 473 women aged 60 or over with a
clinically negative axilla were randomly assigned to undergo
primary surgery plus axillary clearance followed by tamoxifen, or
surgery without axillary dissection followed by tamoxifen (IBCSG,
1996). At a median follow-up of 6.6 years there were no differences
between the two groups in disease-free or overall survival.
Interestingly in the ALMANAC trial (comparing sentinel node
biopsy and standard axillary treatment), which used validated
measures of patient reported quality of life and arm morbidity,
older women (65 years and over) irrespective of axillary manage-
ment had better quality of life outcomes at all stages of the
18-month follow-up than younger women (Fleissig et al, 2006).
However, perhaps a more fundamental question is whether
surgery can be omitted and replaced by primary endocrine
therapy. In a Cochrane review examining studies comparing
surgery with or without adjuvant tamoxifen and primary endo-
crine therapy with tamoxifen alone, there was no significant
difference in overall survival, but tamoxifen alone was inferior to
surgery in terms of local disease control (Hind et al, 2007). Studies
in this review recruited women of 70 years or over who were fit and
well, and in some studies patients were not selected for ER status.
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The average period of cancer control before progression was
18 to 24 months. Therefore the survival of very old and frail
patients with confirmed ER-positive disease is unlikely to be
adversely affected by the decision to avoid primary surgery.
Subsequently, the question has arisen as to whether aromatase
inhibitors, which have proven slightly superior to tamoxifen in
both the metastatic and adjuvant settings, may be a more
appropriate alternative to surgery. It was planned to address this
prospectively in the ESTEEM (endocrine ± surgical therapy for
elderly women with mammary cancer) trial. ESTEEM was a large
United Kingdom trial that aimed to recruit 1200 patients aged 75
years or over with primary operable oestrogen-receptor (ER)-
positive breast cancer, and randomise them to receive primary
endocrine therapy with anastrozole or surgery plus adjuvant
anastrozole. A key component of this trial was the inclusion of frail
patients who could undergo surgery under local anaesthetic and
the extensive use of geriatric assessments, including measurements
of co-morbidities, cognitive function and functional status,
in order to characterise better those who might benefit.
Unfortunately, ESTEEM closed early owing to slow recruitment.
The early closure of ESTEEM and other studies in this population
of patients (see below) demonstrates the challenges associated with
non-blinded studies, with major differences between the groups
and a direct comparison of the approaches is not likely to be
forthcoming.
At present, the optimal approach is to use standard surgical
approaches including SNB for all patients with estimated survivals
of at least several years. However, primary endocrine therapy is a
reasonable alternative for patients with a limited life expectancy
(o2–3 years) due to multiple co-morbidities or extreme old age.
ADJUVANT RADIOTHERAPY
Adjuvant radiotherapy is the current standard of care for patients
with early breast cancer following breast-conserving surgery, and
in patients with a high risk of local recurrence following
mastectomy. According to the Oxford overview analysis: in women
undergoing breast-conserving surgery, 5-year local recurrence
risks were 7 vs 26% (2Po0.00001) and a 15-year breast cancer
mortality risks 30.5 vs 35.9% (2P¼ 0.0002), in those who under-
went radiotherapy following surgery compared with those under-
going surgery alone (EBCTCG, 2005a). Radiotherapy following
breast-conserving surgery was associated with similar proportional
reductions in local recurrence across all age groups. However, the
absolute benefits of treatment were lower in older patients as their
overall risk of local recurrence was less (absolute reductions in
5-year local recurrence risk for post-BCS radiotherapy: 22, 16, 12
and 11% for those aged o50, 50–59, 60–69 and X70 years,
respectively; test for trend in absolute benefits 2P¼ 000002).
There was, however, also an excess of non-breast cancer mortality
in women undergoing radiotherapy, largely from heart disease
(rate ratio 1.27, 2P¼ 0.0001) and lung cancer (rate ratio 1.78,
2P¼ 0.0004). It seems likely that these risks are lower with more
modern radiotherapy techniques, although older patients probably
remain those at greatest risk.
One important large randomised trial has directly addressed
the role of adjuvant radiotherapy following breast-conserving
surgery in older women (Hughes et al, 2010). In this study
women aged 70 years or more with T1 N0 hormone receptor-
positive breast cancers who had undergone breast-conserving
surgery and were being treated with tamoxifen, were randomised
to receive radiotherapy or not. At the most recent update
(at a median follow up of 10.5 years), the rate of local or regional
recurrence was 9% in those treated with tamoxifen alone,
and 2% in those who also received radiotherapy (Po0.001). There
were no significant differences between the two groups in overall
survival.
Aromatase inhibitors have a favourable impact on local recurrence
when compared with tamoxifen (ATAC Trialists, 2008). Taken
together with recent trends for falling local recurrence rates, these
factors are likely to further reduce the already low local recurrence
rates seen in older patients, and may mean that the absolute benefits
of radiotherapy in this population in the future will be smaller still.
The PRIME II (post-operative radiotherapy in minimum-risk elderly
phase II) trial has recruited women aged 65 or over with low-risk
breast cancer (p3 cm, grade I or II, node negative and hormone-
receptor positive), treated by breast-conserving surgery and adjuvant
endocrine therapy (Kunkler, 2004). Patients were randomised to
receive post-operative breast radiotherapy or no radiotherapy, and
the trial was designed to detect a difference in local recurrence rates
of at least 5%. The trial completed recruitment in November 2009
and the results were awaited.
At present post-operative radiotherapy remains the standard of
care in older patients undergoing breast-conserving surgery,
except in those very frail patients with a limited life expectancy.
It is frequently reported that older patients are much more likely to
be treated with breast-conserving surgery alone (Lavelle et al, 2007,
Schonberg et al, 2010). The reasons are likely to be multifactorial,
including issues relating to the surgeon and the oncologist, service
practicalities and patients’ wishes. However, older patients with
tumours at higher risk for local recurrence and reasonable life-
spans should be offered irradiation.
Over recent years two studies have compared a previous
standard schedule of 50Gy in 25 fractions with shorter schedules
of 15–16 fractions over 21 and 22 days, respectively (Whelan et al,
2010, START Trialists, 2008). In these studies 11.5 and 17% of
patients were aged 70 or over. There were no significant differences
in efficacy between the treatment strategies, with the shorter
fractionation schedule providing convenience to patients and
reduced healthcare expenditure. In the future, hypofractionation,
partial breast irradiation, brachytherapy and intraoperative radio-
therapy, may all mean that radiotherapy can be more efficiently
delivered. Such developments involving fewer visits may be of
particular relevance to older patients.
ADJUVANT CHEMOTHERAPY
Compared with their younger counterparts, older women are more
likely to have low-grade, oestrogen receptor-positive tumours
(Mustacchi et al, 2007). As a consequence, endocrine therapy has
been the mainstay of adjuvant systemic therapy for the older age
group. However, a significant proportion of older women do still
present with tumours with adverse prognostic features, suggesting
a significant risk of disease recurrence (Mustacchi et al, 2007). The
current life expectancy of a 70-year-old woman in the United
Kingdom is 16 years. Therefore many older women with breast
cancer are at risk of recurrence and death from breast cancer in
their projected lifetime, and may potentially benefit from
chemotherapy (Office for National Statistics, 2010).
In the Oxford overview of the Early Breast Cancer Trialists’
Collaborative Group, published in 2005, the benefits of poly-
chemotherapy were seen to decrease progressively with increasing
age. The reductions in risk of death for polychemotherapy
compared with no chemotherapy were 30, 15, 9 and 13% for the
age groups 40–49, 50–59, 60–69 and 70 and over, respectively
(EBCTCG, 2005b). Hence the benefit for patients aged 70 or over
was of the same order as for younger postmenopausal women, but
this result was not significant as the number of older women in the
analysis was small (only 4% of women included in the trials
analysed were aged 70 years or over) (EBCTCG, 2005b). The value
of programmes such as Adjuvant! Online may be limited in this
patient population, as the predictive estimates are based
on clinical trials where older patients are under-represented.
The role of gene expression analyses such as Oncotype
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Dx (Genomic Health, Redwood City, CA, USA) and Mammaprint
(Agendia BV, Amsterdam, The Netherlands) to help identify those
most likely to benefit from adjuvant chemotherapy may be of
particular help in older patients, but to date no studies have been
conducted specifically in this age group.
Two contemporary trials, adjuvant cytotoxic chemotherapy in
older women (ACTION) and chemotherapy adjuvant study for
women at advanced age (CASA), planned to examine the benefits of
adjuvant chemotherapy in women aged over 70 years and 65 years,
respectively, with ER-negative or high-risk ER-positive tumours.
Both trials included chemotherapy and no chemotherapy arms, in an
attempt to quantify the absolute gains from chemotherapy.
Unfortunately both trials closed due to poor recruitment. Therefore,
the available data suggest that there may be a benefit to adjuvant
systemic chemotherapy in some older women with breast cancer, but
which patients benefit and the magnitude of the benefit are
unknown. Table 1 summarises current and recently closed trials of
adjuvant chemotherapy in older women.
The Cancer and Leukemia Group B (CALGB) 49907 study took
as a premise that adjuvant chemotherapy is of benefit in older
women, and has compared two treatment regimens (Muss et al,
2009). Women aged 65 or older with invasive T1–T4 breast cancer
(ER positive or negative) and node positive or negative, were
randomised to receive standard chemotherapy (six cycles of CMF
or four cycles of AC, according to physician choice), or six cycles
of oral capecitabine. Accrual stopped at 633 patients, at which
point 61% of patients were aged 70 years or over. After a median
follow-up of 2 years, patients randomised to capecitabine were 2.4
times more likely to experience a relapse-free survival event (95%
CI: 1.5–3.8; adjusted P¼ 0.0003) and 2.1 times more likely to die
(95% CI: 1.2–3.7; P¼ 0.02) than those receiving standard
chemotherapy. This trial shows that there is a benefit to giving
patients over 65 with a good performance status standard
polychemotherapy compared with single agent capecitabine
chemotherapy. An unplanned subset analysis in this trial showed
that the major benefit for standard chemotherapy was in patients
with hormone receptor-negative tumours.
In younger patients dose-dense adjuvant chemotherapy regi-
mens are often used, however, in the pivotal CALGB 9741 trial
demonstrating the benefits of the dose-dense approach only 3% of
patients were aged 70 or over (Citron et al, 2003). The concurrent
dose-dense regimens were associated with more red-cell transfu-
sions, more grade-3 emesis and more post-chemotherapy neuro-
toxicity than the sequential approach, all of which may be
particularly relevant in older patients. Toxicity is likely to be a
key factor when considering adjuvant chemotherapy in older
patients. In a large retrospective review of four CALGB trials of
adjuvant chemotherapy, treatment-related mortality was found to
be related to age: 0.2% (p50 years), 0.7% (51–64 years) and 1.5%
(X65 years) (Po0.001) (Muss et al, 2005). Age is also a significant
risk factor for congestive cardiac failure in women receiving
adjuvant chemotherapy for breast cancer (HR, 1.79 per 10 years;
95% CI: 1.66–1.93) (Pinder et al, 2007). The US Oncology group
has compared an anthracycline (doxorubicin/cyclophosphamide)
with a non-anthracycline (docetaxel/cyclophosphamide) regimen
in the adjuvant treatment of operable breast cancer (Jones et al,
2007). The non-anthracycline arm was found to be superior to the
anthracycline treatment, including in the 16% of patients who were
aged 65 or over at study entry. Owing to the low risks of
cardiotoxicity and acceptable neutropaenic sepsis rate, this regi-
men has become popular with many oncologists treating older
women. It should be emphasised, however, that much of the
available data regarding treatment-related toxicities relate to
clinical trial populations of older women with breast cancer. It is
likely that in the less-selected general population of older women
with breast cancer that toxicity rates may be even higher.
ENDOCRINE THERAPY
The efficacy of adjuvant endocrine therapy in older patients is well
established. In women with ER-positive breast cancer, 5 years of
adjuvant tamoxifen reduces the annual risks of recurrence and
breast cancer mortality by 39 and 31%, respectively, irrespective of
age (o50, 50–69, X70 years (EBCTCG, 2005b). With the
emergence of aromatase inhibitors in the adjuvant setting in
postmenopausal women, clinical trials of endocrine therapy have
inevitably studied older populations. In the ATAC and BIG 1.98
studies, the benefits of aromatase inhibitors over tamoxifen in the
adjuvant treatment of breast cancer were seen across all age groups
(ATAC Trialists, 2008 and Crivellari et al, 2008). However, in the
BIG 1-98 study older patients (X75 years) were less likely to
Table 1 Randomised trials of adjuvant chemotherapy in older women with breast cancer
Name/group Study population Control arm Experimental arm Status
ACTION (UK NCRN) Age X70.
ER negative or high-risk ER
positive.
If ER negative: nil.
If ER positive: endocrine
therapy.
Four cycles AC or EC.
2nd randomisation 2 weekly vs
3 weekly with GCSF.
Closed owing to poor
recruitment.
CALGB 49907 Age X65. LN positive or high-risk
LN negative. Any ER.
Four cycles AC or six
cycles CMF.
If ER positive: endocrine
therapy.
Six cycles capecitabine.
If ER positive: endocrine therapy
Completed and published
(Muss et al, 2009).
CASA (IBCSG/BIG) AgeX65. LN positive or negative.
ER negative.
Nil or low-dose
metronomic
methotrexate.
Eight cycles of pegylated liposomal
doxorubicin (2 weekly)
Closed owing to poor
recruitment.
ELDA (National
Cancer Institute,
Naples)
Age 65–80. ER and PgR negative
or LN positive, or 420mm, or
G2/3.
IV CMF (four or six
cycles)
Weekly docetaxel (days 1, 8, 15 q
28) (four or six cycles)
Open to recruitment.
ICE (German Breast
Group)
AgeX65. LN positive or high-risk
node negative. Any ER status.
Ibandronate.
If ER positive: anastrazole.
Ibandronate and six cycles
capecitabine.
If ER positive: anastrozole.
Closed to recruitment:
efficacy results awaited.
ICE II (German Breast
Group)
AgeX65. pT1/2 and pN0/1 with
an increased risk based on either
uPA/PAI1 or clinico-pathological
risk parameters.
Four EC or six CMF Six cycles of weekly nab-paclitaxel
(days 1, 8, 15 q22 with a week of
rest every 6 weeks) with
capecitabine (days 1–14, q21)
Open to recruitment.
Abbreviations: AC¼ doxorubicin/cyclophosphamide; ACTION¼ adjuvant cytotoxic chemotherapy in older women; CALGB¼Cancer and Leukemia Group B;
CASA¼ chemotherapy adjuvant study for women at advanced age; CMF¼ cyclophosphamide, methotrexate and 5-fluorouracil; EC¼ epirubicin/cyclophosphamide;
ER¼ oestrogen receptor; LN¼ lymph node; PgR=progesterone receptor.
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complete trial treatment, although the rates of discontinuation
were similar in the letrozole and tamoxifen treatment groups
(Crivellari et al, 2008). The well-described increased bone loss
during treatment with aromatase inhibitors coupled with the
typical decline in bone mineral density (BMD) with age, makes
attention to bone health of particular importance in the older
patient. Bone protection with a bisphosphonate is required not
only in those with low BMD (T score o2), but also in patients
over 75 with one or more additional risk factors for fracture (Reid
et al, 2008). Bisphosphonates have been shown to prevent bone
loss during treatment with aromatase inhibitors, including in those
with pre-existing osteoporosis (van Poznak et al, 2010). Therefore
decisions on choice of endocrine therapy in the elderly, as in
younger patients, should be based on the biology and risk of
recurrence of the underlying breast cancer, rather than the level of
BMD. Other than bone health other differences in the relative
toxicity profiles of aromatase inhibitors, such as with regard
cerebrovascular, thromboembolic events and potentially muscu-
loskeletal complaints may influence choice of agent.
ADJUVANT TRASTUZUMAB
The proportion of breast cancers which are HER2 positive appears
to be similar or slightly lower than that seen in younger women
with around 10–16% of tumours in women aged 65 and over
testing positive (Mustacchi et al, 2007). Only 16% of the patients
entering the HERA and NSABP B31/N9831 trials were aged 60 or
over, but the benefits of trastuzumab in this subgroup appeared to
be same as for the whole-study populations (Smith et al, 2007 and
Romond et al, 2005). Trastuzumab-induced cardiac dysfunction
might be a particular concern in older patients. In the HERA trial
the incidence of cardiac adverse events for those 60 years or over,
compared with those less than 60 years was not significantly
different (3.75 vs 3.61%; difference in incidence 0.14% (95% CI:
2.54-2.80)) (Suter et al, 2007). Moreover, trastuzumab-induced
cardiac toxcity is usually reversible. However, the number of
patients over the age of 60 was small, and patients with known
cardiac disease or a left ventricular ejection fraction of less than
55% after chemotherapy were excluded. Therefore although it
would be reasonable to conclude that age is not a risk factor for
cardiac dysfunction, there are limited data and a significant
number of elderly patients may not be eligible for treatment with
trastuzumab based on pre-existing co-morbidities. Measures to
reduce the risks of cardiac toxicity such as the use of non-
anthracycline regimens such as the docetaxel, carboplatin and
trastuzumab (‘TCH’) regimen, and ongoing trials examining
shorter durations of adjuvant trastuzumab may be particularly
relevant in older patients. Although some clinicians do use
trastuzumab without chemotherapy in the adjuvant setting, there
are no data to support this approach.
CONCLUSIONS
The data discussed in this review and the information emerging
from ongoing clinical trials provide a framework for the manage-
ment of breast cancer in older women. In essence, older patients
should be treated according to tumour biology as for younger
patients, except where co-morbidities or frailty are likely to
mitigate the benefits of treatment or mean that treatment will not
be tolerated. However, there are some fundamental questions
regarding everyday management, which remain unanswered
(Table 2). Perhaps, the biggest challenge is to apply the available
evidence in the clinic to the individual older patient. Patients over
the age of 70 represent a highly heterogeneous population in terms
of co-morbidities, fitness, life expectancy, social situation,
cognitive function and desire for treatment. Assessment of these
factors taking into account the risks of death from competing
causes of mortality and the likely tolerance of any proposed
treatment is a vital component to making appropriate informed
decisions regarding adjuvant treatment. Assessment tools to do
this have been developed, but most require validation in patients
with cancer (Extermann and Hurria, 2007). It is imperative that we
do this in order that we can best serve the ageing population of
women with breast cancer.
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